Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.
Subscribe to see Vivos Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Vivos Therapeutics, Inc. is a medical devices company headquartered in Littleton, United States. It is publicly listed (VVOS) with a market capitalisation of $2.3M. Xcout tracks 18 named people at Vivos Therapeutics, Inc., including Jennifer Hauser (Executive Assistant to CEO and Chairman & CFO).
12 more named people on record for Vivos Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
A few of Vivos Therapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
LuminX Global, Inc. develops medical devices and diagnostic software for dentistry, specifically focusing on subgingival diagnostics for gum disease detection. Its flagship product, the LuminX Probe, uses sensor-based measurements and imaging technology to automate periodontal charting for dental professionals, hygienists, and periodontists.
PAVmed Inc. operates as a U.S.-based medical technology firm. Its principal commercialized products include CarpX, a percutaneous device designed to address carpal tunnel syndrome. Other key offerings are EsoCheck, an esophageal cell collection device vital for the early detection of esophageal adenocarcinoma and Barrett's Esophagus (BE), and EsoGuard, a specialized bisulfite-converted next-generation sequencing DNA assay. The company's extensive development pipeline further encompasses EsoCure, an esophageal ablation device intended to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; and NextFlo, a disposable infusion platform technology. Also in development are the Veris cancer healthcare platform, which features an intelligent vascular port for combined remote monitoring and data analytics, alongside Veris cardiac monitors. Additional innovations include NextVent single-use ventilators, FlexMO medical circulatory support cannulas, DisappEAR resorbable pediatric ear tubes, and Solys for noninvasive glucose monitoring. Established in 2014, the enterprise originally traded as PAXmed Inc. before rebranding to PAVmed Inc. in April 2015. Its corporate headquarters are located in New York, New York.
NIOX Group Plc is a worldwide company dedicated to innovating, developing, and distributing medical devices that measure fractional exhaled nitric oxide (FeNO). A key product is the NIOX VERO system, an easily portable and non-invasive diagnostic tool designed for immediate, on-site patient use. This system includes a compact device alongside a suite of disposable items like sensors, individual mouthpieces, and breathing handles, all essential for quantifying FeNO levels in patients. The company, which was founded in 2006 and is headquartered in Oxford, United Kingdom, was formerly known as Circassia Group Plc until its renaming to NIOX Group Plc in September 2022.
Osstell is a dental technology company headquartered in Gothenburg, Sweden. The company specializes in product solutions for dental implants and provides diagnostic tools used in more than 70 countries.
EvoEndo, Inc. is a medical technology company based in Denver, Colorado, that specializes in sedation-free transnasal endoscopy (TNE). The company provides specialized medical devices and pediatric-friendly procedures for gastrointestinal examinations. EvoEndo's products are designed for use by trained physicians to perform unsedated endoscopies.
Dror Ortho-Design, Inc. engages in the research and development of an orthodontic alignment platform. Its platform consists of ZSmile smartphone application that allows patients to make a video of their smile and teeth, and upload the video to the ZSmile AI Cloud platform; ZSmile AI Cloud, an AI-based cloud service to perform analytics and manage patient treatment plans; and base control unit that consists of the pump and the IoT components, as well as a smart aligner, which includes the micro-balloon that pushes teeth into their intended final position using pulsating air. The company was formerly known as Novint Technologies, Inc. and changed its name to Dror Ortho-Design, Inc. in September 2023. Dror Ortho-Design, Inc. was incorporated in 1999 and is based in Jerusalem, Israel.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.